Day One Biopharmaceuticals (DAWN) Competitors $6.80 +0.07 (+1.04%) Closing price 07/3/2025 03:00 PM EasternExtended Trading$6.80 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. OGN, AMRX, MIRM, XENE, BHC, IBRX, GMTX, ARWR, APLS, and TWSTShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Organon & Co. (OGN), AMNEAL PHARMACEUTICALS (AMRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors Organon & Co. AMNEAL PHARMACEUTICALS Mirum Pharmaceuticals Xenon Pharmaceuticals Bausch Health Cos ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience Organon & Co. (NYSE:OGN) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Do analysts recommend OGN or DAWN? Organon & Co. presently has a consensus target price of $18.00, suggesting a potential upside of 78.66%. Day One Biopharmaceuticals has a consensus target price of $30.57, suggesting a potential upside of 349.58%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to OGN or DAWN? In the previous week, Organon & Co. had 48 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 49 mentions for Organon & Co. and 1 mentions for Day One Biopharmaceuticals. Organon & Co.'s average media sentiment score of 0.03 beat Day One Biopharmaceuticals' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 4 Very Positive mention(s) 3 Positive mention(s) 37 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Day One Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, OGN or DAWN? Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.27, meaning that its share price is 227% less volatile than the S&P 500. Do institutionals and insiders hold more shares of OGN or DAWN? 77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 2.0% of Organon & Co. shares are held by company insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is OGN or DAWN more profitable? Organon & Co. has a net margin of 11.92% compared to Day One Biopharmaceuticals' net margin of -42.66%. Organon & Co.'s return on equity of 227.43% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.92% 227.43% 7.34% Day One Biopharmaceuticals -42.66%-14.98%-13.04% Which has preferable earnings & valuation, OGN or DAWN? Organon & Co. has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.41$864M$2.883.50Day One Biopharmaceuticals$131.16M5.26-$95.50M-$0.71-9.58 SummaryOrganon & Co. beats Day One Biopharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$689.27M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-9.5821.5627.5220.22Price / Sales5.26281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book1.367.518.045.67Net Income-$95.50M-$55.05M$3.18B$249.13M7 Day Performance5.10%4.61%2.90%3.28%1 Month Performance-2.16%4.72%3.70%5.55%1 Year Performance-50.40%5.92%36.15%21.12% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals1.7556 of 5 stars$6.80+1.0%$30.57+349.6%-49.6%$689.27M$131.16M-9.5860Upcoming EarningsOGNOrganon & Co.4.8946 of 5 stars$9.68-1.8%$18.00+86.0%-50.4%$2.56B$6.40B3.364,000Trending NewsAMRXAMNEAL PHARMACEUTICALS3.7828 of 5 stars$8.09-0.5%$11.60+43.4%+26.8%$2.55B$2.79B-202.208,100High Trading VolumeMIRMMirum Pharmaceuticals3.731 of 5 stars$50.89-0.4%$65.50+28.7%+47.4%$2.53B$336.89M-31.61140News CoveragePositive NewsXENEXenon Pharmaceuticals2.9954 of 5 stars$31.30-3.4%$54.82+75.1%-3.9%$2.49B$9.43M-9.69210BHCBausch Health Cos3.1352 of 5 stars$6.68+3.4%$7.42+11.0%-2.8%$2.39B$9.63B-60.7320,700IBRXImmunityBio1.8722 of 5 stars$2.64-2.2%$12.25+364.0%-57.0%$2.38B$14.74M-4.55590Negative NewsGap UpGMTXGemini TherapeuticsN/A$54.50+0.7%N/A+23.2%$2.36BN/A-54.5030High Trading VolumeARWRArrowhead Pharmaceuticals3.9959 of 5 stars$15.80-1.7%$43.71+176.7%-33.1%$2.22B$3.55M-11.29400Positive NewsAPLSApellis Pharmaceuticals4.4456 of 5 stars$17.31-0.7%$40.05+131.4%-49.2%$2.19B$781.37M-9.67770Trending NewsAnalyst ForecastAnalyst RevisionTWSTTwist Bioscience4.4751 of 5 stars$36.79+2.4%$50.40+37.0%-20.6%$2.15B$312.97M-11.32990 Related Companies and Tools Related Companies Organon & Co. Competitors AMNEAL PHARMACEUTICALS Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Bausch Health Cos Competitors ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Twist Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DAWN Stock Alerts